Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Cyclin dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) are effective in breast cancer; however, drug resistance is frequently encountered and poorly understood. We conducted a genomic analysis of 348 estrogen receptor-positive (ER+
) breast cancers treated with CDK4/6i and identified loss-of-function mutations affecting FAT1 and RB1 linked to drug resistance. FAT1 loss led to marked elevations in CDK6, the suppression of which restored sensitivity to CDK4/6i. The induction of CDK6 was mediated by the Hippo pathway with accumulation of YAP and TAZ transcription factors on the CDK6 promoter. Genomic alterations in other Hippo pathway components were also found to promote CDK4/6i resistance. These findings uncover a tumor suppressor function of Hippo signaling in ER+
breast cancer and establish FAT1 loss as a mechanism of resistance to CDK4/6i.
Li, Z; Razavi, P; Li, Q; Toy, W; Liu, B; Ping, C; Hsieh, W; Sanchez-Vega, F; Brown, DN; Da Cruz Paula, AF; Morris, L; Selenica, P; Eichenberger, E; Shen, R; Schultz, N; Rosen, N; Scaltriti, M; Brogi, E; Baselga, J; Reis-Filho, JS; Chandarlapaty, S
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)